Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker identification of radiation responses after 177Lu-DOTATATE PRRT
NL-OMON51484Completed
- Sponsor
- Moleculaire genetica
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Moleculaire genetica. Started Jan 2023; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON51484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51484.